The two drugmakers recalled the extended-release tablets after detecting unacceptable levels of N-Nitrosodimethylamine, a probable human carcinogen.
Teva is recalling 14 lots of its metformin hydrochloride extended-release tablets in the U.S., including their 500 mg and 750 mg bottles.
Marksans Pharma Limited, which is based in India, is recalling one lot of its extended-release metformin tablet in the U.S.
The recalls come after the FDA determined May 28 that there were unacceptable levels of N-Nitrosodimethylamine in metformin extended-release tablets.
Two other drugmakers, Apotex and Amneal Pharmaceuticals have both recalled their extended-release tablets after being asked to do so by the FDA.
The agency had asked five drugmakers to voluntarily recall their products.
More articles on pharmacy:
Pharmacist salaries across the most common work settings
FDA asks 5 drugmakers to recall metformin products
Remdesivir could make billions for Gilead, analyst says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
